Depression Clinical Trial
Official title:
Investigation of the Rapid (Next Day) Antidepressant Effects of an NMDA Antagonist
Depressive disorders may be severe, chronic and often life-threatening illnesses. Impairment
in physical and social functioning resulting from depression can be just as severe as other
chronic medical illnesses. Recent preclinical and clinical studies suggest that the
glutamatergic system is involved in the mechanism of action of antidepressants.
This study examines whether ketamine can cause a rapid-next day antidepressant effect in
patients with Major Depressive Disorder.
This study was designed to address the questions:
Does the NMDA antagonist ketamine produce rapid antidepressant effects in patients with
treatment-resistant major depression? What are the neurobiological correlates of
antidepressant response (examining multi-modal MRI, MEG, polysomnography and serum markers)
Patients, ages 18 to 65 years with treatment-resistant major (unipolar) depression will in a
double-blind crossover study receive either intravenous ketamine or saline solution.
This study will test whether a single dose of ketamine - a drug that blocks a brain receptor
called NMDA - can cause a rapid (next day) antidepressant effect in patients with major
depression. Several medications are effective for treating depression; however, they take
weeks or months to achieve their full effects. A more rapidly acting antidepressant would
have a significant impact on the treatment of depression. In a previous study, ketamine
produced a rapid antidepressant effect within hours, but the effect lasted less than 1 week.
Understanding how ketamine works may lead to a better understanding of the causes of
depression and the design of a longer lasting rapidly acting antidepressant.
Patients between 18 and 65 years of age who are currently experiencing an episode of major
depression of at least 4 weeks duration and have not responded to two treatment trials may be
eligible for this study. Candidates are screened with a medical and psychiatric history,
physical examination, and blood and urine tests.
Participants undergo the following tests and procedures:
Medication tapering: Patients who are taking medications for depression are tapered off the
drugs over a 1- to 2-week period.
Ketamine/placebo trial: Patients are given a single dose of either ketamine or placebo (an
inactive substance), administered intravenously (through a vein) over 40 minutes. After 7
days, patients are given another dose of study drug in crossover fashion; that is, those who
previously took ketamine are switched to receive placebo, and those who took placebo are
switched to ketamine. Oximetry (measurement of blood oxygen), pulse, and blood pressure are
measured continuously for 1 hour before and 4 hours after each ketamine or placebo dose to
monitor safety.
Interviews and rating scales: Patients complete a series of psychiatric rating scales to
assess the effects of the study drug on mood and thinking. The rating scales are repeated up
to 18 times during the study, with each time taking about 15 to 20 minutes.
Physical examination and laboratory tests: Patients have a physical examination, blood tests,
weight measure, and electrocardiogram (ECG) at the beginning and end of the study. They will
also have multi-modal MRI, MEG, polysomnography and serum marker studies.
The primary endpoint will be the change in clinical ratings of depression. Secondary
endpoints will examine neurobiological correlates (i.e., multi-modal MRI, MEG,
polysomnography and serum markers) of antidepressant response to ketamine (compared to
placebo).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05777044 -
The Effect of Hatha Yoga on Mental Health
|
N/A | |
Recruiting |
NCT04977232 -
Adjunctive Game Intervention for Anhedonia in MDD Patients
|
N/A | |
Recruiting |
NCT04680611 -
Severe Asthma, MepolizumaB and Affect: SAMBA Study
|
||
Recruiting |
NCT04043052 -
Mobile Technologies and Post-stroke Depression
|
N/A | |
Completed |
NCT04512768 -
Treating Comorbid Insomnia in Transdiagnostic Internet-Delivered Cognitive Behaviour Therapy
|
N/A | |
Recruiting |
NCT03207828 -
Testing Interventions for Patients With Fibromyalgia and Depression
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT06011681 -
The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over
|
||
Completed |
NCT04476446 -
An Expanded Access Protocol for Esketamine Treatment in Participants With Treatment Resistant Depression (TRD) Who do Not Have Other Treatment Alternatives
|
Phase 3 | |
Recruiting |
NCT02783430 -
Evaluation of the Initial Prescription of Ketamine and Milnacipran in Depression in Patients With a Progressive Disease
|
Phase 2/Phase 3 | |
Recruiting |
NCT05563805 -
Exploring Virtual Reality Adventure Training Exergaming
|
N/A | |
Completed |
NCT04598165 -
Mobile WACh NEO: Mobile Solutions for Neonatal Health and Maternal Support
|
N/A | |
Completed |
NCT03457714 -
Guided Internet Delivered Cognitive-Behaviour Therapy for Persons With Spinal Cord Injury: A Feasibility Trial
|
||
Recruiting |
NCT05956912 -
Implementing Group Metacognitive Therapy in Cardiac Rehabilitation Services (PATHWAY-Beacons)
|
||
Completed |
NCT05588622 -
Meru Health Program for Cancer Patients With Depression and Anxiety
|
N/A | |
Recruiting |
NCT05234476 -
Behavioral Activation Plus Savoring for University Students
|
N/A | |
Active, not recruiting |
NCT05006976 -
A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study
|
N/A | |
Enrolling by invitation |
NCT03276585 -
Night in Japan Home Sleep Monitoring Study
|
||
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A |